Vitestro Raises $70 Million in Oversubscribed Series B Financing to Advance Autonomous Robotic Phlebotomy and Commercial Readiness
Labcorp Venture Fund, Mayo Clinic, Sutter Health, InterVest, MGFO, PGGM, Puma Venture Capital, and ROM Utrecht invest alongside existing investors Invest-NL, EIC Fund, Fred Moll, NYBC Ventures, and Sonder Capital.
Utrecht, The Netherlands, March 10, 2026 – Vitestro, the pioneer in medical robotics advancing automated diagnostic blood collection, today announced the close of a $70 million oversubscribed Series B financing. The round includes new strategic investment from U.S. healthcare leaders Labcorp Venture Fund, Mayo Clinic, and Sutter Health, new financial investors InterVest, MGFO, PGGM, Puma Venture Capital, and ROM Utrecht, and continued support from existing investors Invest-NL (supported by InvestEU), EIC Fund, Fred Moll, NYBC Ventures, and Sonder Capital.
Proceeds will be used to advance the next generation Aletta® Autonomous Robotic Phlebotomy Device® (ARPD™), enabling deeper integration into high-volume clinical workflows. The funding will also support Vitestro’s U.S. FDA De Novo regulatory pathway and global commercial readiness, including manufacturing scale-up, clinical expansion, and commercial infrastructure development, as the company prepares for broader market adoption beginning in Europe and progressing toward the U.S. market.
